Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Cyprus has been experiencing steady growth over the past few years.
Customer preferences: There has been a growing demand for Anti-Hypertensive Drugs in Cyprus due to the increasing prevalence of hypertension among the population. The aging population and unhealthy lifestyle choices have contributed to this trend. Patients in Cyprus generally prefer to purchase Anti-Hypertensive Drugs from local pharmacies and hospitals. However, there has been a shift towards online purchases due to the convenience and accessibility offered by e-pharmacies.
Trends in the market: The Anti-Hypertensive Drugs market in Cyprus is expected to continue its growth trajectory in the coming years. The market is being driven by the increasing prevalence of hypertension, the growing aging population, and the availability of innovative drugs. The market is also witnessing a shift towards combination therapies, which offer better efficacy and convenience to patients. Additionally, there is a growing trend towards the use of generic drugs, which are more cost-effective and offer similar therapeutic benefits as branded drugs.
Local special circumstances: Cyprus is a small island nation with a population of approximately 1.2 million people. The healthcare sector in Cyprus is primarily funded by the government, with a significant portion of the population covered by the National Health Scheme. However, there is also a growing private healthcare sector, which is driving the demand for Anti-Hypertensive Drugs in the country. Additionally, the country's geographical location and proximity to Europe and the Middle East make it an attractive market for pharmaceutical companies.
Underlying macroeconomic factors: The Cypriot economy has been experiencing steady growth over the past few years, with a focus on diversifying the economy and attracting foreign investment. The healthcare sector is a key focus area for the government, with significant investments being made in the sector. Additionally, the country's membership in the European Union has facilitated the import and export of pharmaceuticals, contributing to the growth of the Anti-Hypertensive Drugs market in Cyprus.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
